- Home
- TCRX vs PSTV Comparison
TCRX vs PSTV Comparison
Compare TCRX & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- PSTV
- Stock Information
- Founded
- TCRX 2018
- PSTV 1996
- Country
- TCRX United States
- PSTV United States
- Employees
- TCRX N/A
- PSTV N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- TCRX Health Care
- PSTV Health Care
- Exchange
- TCRX Nasdaq
- PSTV Nasdaq
- Market Cap
- TCRX 64.1M
- PSTV 61.1M
- IPO Year
- TCRX 2021
- PSTV N/A
- Fundamental
- Price
- TCRX $0.98
- PSTV $0.49
- Analyst Decision
- TCRX Strong Buy
- PSTV Strong Buy
- Analyst Count
- TCRX 7
- PSTV 4
- Target Price
- TCRX $8.50
- PSTV $7.75
- AVG Volume (30 Days)
- TCRX 1.1M
- PSTV 5.9M
- Earning Date
- TCRX 11-12-2025
- PSTV 10-30-2025
- Dividend Yield
- TCRX N/A
- PSTV N/A
- EPS Growth
- TCRX N/A
- PSTV N/A
- EPS
- TCRX N/A
- PSTV N/A
- Revenue
- TCRX $8,423,000.00
- PSTV $5,258,000.00
- Revenue This Year
- TCRX $255.18
- PSTV $9.91
- Revenue Next Year
- TCRX N/A
- PSTV $1.06
- P/E Ratio
- TCRX N/A
- PSTV N/A
- Revenue Growth
- TCRX N/A
- PSTV N/A
- 52 Week Low
- TCRX $0.96
- PSTV $0.16
- 52 Week High
- TCRX $4.94
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- TCRX 28.55
- PSTV 40.74
- Support Level
- TCRX $0.96
- PSTV $0.46
- Resistance Level
- TCRX $1.25
- PSTV $0.56
- Average True Range (ATR)
- TCRX 0.13
- PSTV 0.05
- MACD
- TCRX -0.02
- PSTV -0.00
- Stochastic Oscillator
- TCRX 4.00
- PSTV 23.17
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).